News

August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with...

New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest...

Sunshine Heart's C-Pulse System Heart Failure Treatment

Sunshine Heart Inc. announced that the current condition of a heart failure patient implanted with the C-Pulse System improved after six weeks of treatment, allowing him to attend his daughter's...

The Healthcare Accreditation Colloquium announced that Texas Children's Hospital has earned the designation of Accredited Pediatric Heart Failure Institute following 12 months of work and an...

MYDICAR Celladon Corp. Clinical Trial Heart Failure Treatments LVADs

Celladon Corp. announced that the first patient has been dosed in a clinical trial titled "Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with Heart Failure...

SynCardia Total Artificial Heart SynHall Valves FDA approval

SynCardia Systems Inc. received approval in July from the U.S. Federal Drug Administration (FDA) for the SynCardia temporary Total Artificial Heart with SynHall valves, giving the company control...

August 7, 2014 — The Berlin Heart Group announced they have completed enrollment in their post-approval study, the only condition of the humanitarian device exemption (HDE) approval that...

August 6, 2014 — St. Jude Medical announced the Center for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment (NTAP) for the CardioMEMS heart failure (HF)...

SynCardia Total Artificial Heart Implant VAD Heart Failure Treatments

For the first time, cardiac surgeons, medical professionals and the public can watch the implantation of the SynCardia temporary Total Artificial Heart in a peer reviewed case report paper and...

CardioVascular Institute Clinical Trial Heart Failure Treatment Parachute

Following a heart attack, many heart failure patients suffer from enlargement of their left ventricle, diminishing the amount of blood the heart can pump to the body and resulting in life-...

The Healthcare Accreditation Colloquium announced that Texas Children's Hospital has earned the designation of Accredited Pediatric Heart Failure Institute following 12 months of work and an...

Syncardiac, driver, artificial heart

July 18, 2014 — The Freedom portable driver has received U.S. Food and Drug Administration (FDA) approval for use with the SynCardia temporary total artificial heart as a bridge to transplantation...

CorMatrix Cardiovascular ECM Enrollment RESTORE Study Poland

CorMatrix Cardiovascular and the Central Clinical Hospital of the Ministry of Interior in Warsaw (Centralny Szpital Kliniczny MSW) of Warsaw, Poland, announced the successful enrollment and...

DC Devices Inc. has closed a $34 million Series D financing round. Accelmed led the round with contributions from existing investors Third Rock Ventures, General Catalyst Partners and Lumira...

In the current era of healthcare reform with the overarching goal of reducing healthcare costs, heart failure (HF) management has taken center stage. It is the leading cause of hospitalization for...

Thoratec Corp. has acquired Apica Cardiovascular Ltd. for an upfront cash payment of $35 million and potential future clinical and sales milestones of up to $40 million. 

Revivent Myocardial Anchoring System BioVentrix 50th Heart Failure Treatment

BioVentrix announced the successful completion of it 50th clinical case using the Revivent myocardial anchoring system in a 74-year-old male patient at the OLV Hospital in Aalst, Belgium....

June 23, 2014 — Men who reported being sedentary, with low levels of physical activity, were at a significantly higher risk for heart failure than those who were more active, according to a Kaiser...

Watchman, LAA occluder

Interventional thought leaders at the American College of Cardiology (ACC) 2014 meeting shared their predictions about the cutting-edge technologies emerging today that will become commonplace in...

Mast Therapeutics Failure MST-188 Clinical Study Pharmaceuticals

Mast Therapeutics Inc. announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of...